Acceptability of Using Real-World Data to Estimate Relative Treatment Effects in Health Technology Assessments: Barriers and Future Steps-Reference-Cited by-同舟云学术

Acceptability of Using Real-World Data to Estimate Relative Treatment Effects in Health Technology Assessments: Barriers and Future Steps

Published:2024-05 Issue:5 Volume:27 Page:623-632
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Gomes Manuel,Turner Alex J.,Sammon Cormac,Dawoud Dalia,Ramagopalan Sreeram,Simpson Alex,Siebert Uwe

Funder

F. Hoffmann-La Roche

Horizon 2020

National Institute for Health and Care Research

European Federation of Pharmaceutical Industries and Associations

Horizon 2020 Framework Programme

European Commission

Innovative Medicines Initiative

F. Hoffmann-La Roche Ltd

Publisher

Elsevier BV

Reference70 articles.

1. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014;Hatswell;BMJ Open,2016

2. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review;Goring;BMJ Open,2019

3. Use of single-arm trials to support malignant hematology and oncology drug and biologic approvals: a 20-year FDA experience;Agrawal;J Clin Oncol,2021

4. Use of external comparators for health technology assessment submissions based on single-arm trials;Patel;Value Health,2021

5. Real-world evidence use in assessments of cancer drugs by NICE;Bullement;Int J Technol Assess,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Next-generation sequencing in oncology: challenges in economic evaluations;Expert Review of Pharmacoeconomics & Outcomes Research;2024-08-11